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New Delhi Metallo-b-lactamase-1 (NDM-1): 
An Emerging Threat Among Enterobacteriaceae
Po-Ren Hsueh1,2
Infections with carbapenem-resistant Enterobacteri-
aceae, particularly Klebsiella pneumoniae, is emerg-
ing as an important challenge in healthcare settings
worldwide.1 Enterobacteriaceae isolates can display
resistance to carbapenems by overexpression 
of Amp-C β-lactamases and extended spectrum
β-lactamases (ESBLs) associated with loss of outer
membrane porins; overexpression of efflux
pumps; and the production of various carbapen-
emases including metallo-β-lactamases (MBLs;
blaIMP, blaVIM, and KHM-1) and K. pneumoniae
carbapenemases (KPCs).2,3
New Delhi metallo-β-lactamase 1 (NDM-1),
a new type of carbapenemase, was first identified
in an isolate from a 59-year-old Swedish man of
Indian origin, who was admitted in New Delhi due
to K. pneumoniae urinary tract infection in 2008.4
As of September 18, 2010, NDM-1 has been iden-
tified in India, Pakistan, Bangladesh, the United
Kingdom, the United States, the Netherlands,
Australia, Kenya, and Canada; and continues to
attract great attention worldwide.4–9 This new
NDM-1 has been recently identified in several
Enterobacteriacae isolates causing community-
onset (e.g. urinary tract infection) or healthcare-
associated infections (e.g. bacteremia and 
ventilator-associated pneumonia).4–9 The species
of the isolates harboring this enzyme included
K. pneumoniae, Escherichia coli, Enterobacter spp.,
Citrobacter freundii, Morganella morganii, and
Providencia spp.4–9
The metallo-β-lactamase gene for NDM-1
(blaNDM-1) is located on plasmids 50–350 kb in
Chennai isolates, 50 kb and 118 kb in Haryana
isolates, and 80–500 kb in the United Kingdom
isolates.6–8 Several isolates in the United Kingdom
harbor the blaNDM-1 gene, suggesting an in situ
translocation of blaNDM-1.4–6 The blaNDM-1 gene, 
together with other coexisting resistance mecha-
nisms, confers a high rate of resistance (> 90%)
to carbapenems (imipenem, meropenem, and
ertapenem) and other β-lactams, aztreonam,
aminoglycosides, and fluoroquinolones.4–9 The
susceptibility rates of isolates from three differ-
ent regions [United Kingdom (n = 37), Chennai-
south India (n = 44) and Haryana-north India
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(n = 26)] to tigecycline and colistin were 56% to
67% and 89% to 100%, respectively.4–6 An iso-
late from Australia has been reported to be suscep-
tible to fosfomycin.6 NDM-1 was distantly related
to other MBLs, sharing only 32% amino acid
identity with the most closely related enzymes
VIM-1 and VIM-2.4–6
In the United Kingdom, carriage of Entero-
bacteriaceae containing blaNDM-1 gene has been
closely linked to receipt of medical care in India
and Pakistan.5 All three isolates reported from the
United States and isolates reported from other
countries were found in patients who had recei-
ved medical care in India recently.4–9 The isolate
in Australia was found in a patient who had re-
turned from Bangladesh.5 Two isolates in the
Netherlands were from two patients who had 
recently returned from a holiday trip in India.
These two patients did not visit any medical care
facility during their trip, but they had taken un-
specified tablets against enteritis.8 Although all of
the UK E. coli and all Chennai isolates were genet-
ically different, 26 NDM-1 positive K. pneumoniae
isolates from Haryana belong to a single PFGE
(pulsed-field gel electrophoresis) profile, suggest-
ing a possibility of clonal spread.7 Plasmid profiles
of the Chennai isolates varied greatly from those
in Haryana, further suggesting the bacterial clon-
ality of NDM-1 carriage in Haryana.5 Although
the relatedness of Indian and UK isolates is not
significant, many of their plasmids are identical
in size, indicating a possibility of plasmid move-
ment (horizontal transfer) between isolates.4–6
The current Centers for Diseases Control
(CDC) infection control guidance for carbapenem-
resistant Enterobacteriaceae is also suitable for
NDM-1-producing isolates.10 This includes active
recognizing carbapenem-resistant Enterobacteri-
aceae when cultured from clinical specimens,
placing patients colonized or infected with these
isolates under contact precautions, and con-
ducting active-surveillance testing among other
high-risk patients. Modified Hodge test, imipenem-
EDTA synergy tests and the MBL E-test (AB
bioMerieux, Solna, Sweden) are used to screen
for MBL production.7 The presence of blaNDM-1 is
also confirmed by polymerase chain reaction with
specific primers targeting the gene.5
The potential for wider international dissemi-
nation of NDM-1-producing isolates or NDM-1-
encoding plasmids to become endemic worldwide
is now a recognized threat. All recent studies iden-
tified NDM-1-producers in India and Pakistan,
evidencing the link between the emergence of
NDM-1-producers in the United Kingdom and
other countries and their possible reservoir in the
Indian subcontinent. On September 9, 2010, the
Taiwan CDC has promulgated the inclusion of
NDM-1-producing Enterobacteriaceae infection in
the list of category IV notifiable infectious dis-
eases. Therefore, clinicians are required to report
this infection to the Taiwan CDC within 24 hours
of diagnosis, according to the case definition that
based on clinical characteristics, epidemiological
links, and laboratory evidence of carbapenem 
resistance in Enterobacteriaceae isolates. As of
September 18, 2010, none of the NDM-1-
producing Enterobacteriaceae infection was re-
ported in Taiwan, although carbapenem resistance
was estimated to be 5–10% among Taiwanese
Enterobacteriaceae isolates studied. Clinicians
should be aware of the risk of NDM-1-producing
Enterobacteriaceae in patients who have received
medical care (including cosmetic or other elec-
tive surgery) within a 6-month period in India,
Pakistan, and other NDM-1-endemic countries.
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